BlueLinx Q4 and Full Year 2025 Results Delivering What Matters February 25, 2026 © BlueLinx 2026. All Rights Reserved. 1 Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements include, without limitation, any statement that predicts, forecasts, indicates or implies future results, performance, liquidity levels or achievements, and may contain the words "believe," "anticipate," "could", "expect," "estimate," "intend," "may", "project," "plan," "should", "will" ...

Financial Data and Key Metrics Changes - Total company revenues increased by 9.1% to $311 million for Q3 2025, with an adjusted EBITDA increase of 12.2% to $164 million, resulting in adjusted EBITDA margins of 52.7%, up 147 basis points year-over-year [4][8] - Net income for Q3 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in Q3 2024 [8][9] - Adjusted EPS increased by $0.09 to $0.26 compared to Q3 2024, driven by adjusted EBITDA growth and a reduced tax rate [4][9] Business Line Data and Key Metrics Changes - **Sterigenics**: Revenue grew by 9.8% to $193 million, with segment income increasing by 11.6% to $107 million and margins improving to 55.6% [9][10] - **Nordion**: Revenue increased by 22.4% to $63 million, with segment income rising by 19.9% to approximately $38 million, although segment income margin decreased to 60.6% due to product mix [10] - **Nelson Labs**: Revenue declined by 5% to $56 million, but segment income rose by 1.9% to $19 million, with margins expanding to 34.1% [11] Market Data and Key Metrics Changes - The company reported strong performance across core medical device customers, with consistent volume recovery in Sterigenics and Nordion [4][24] - Nordion secured a 25-year renewal of its Class 1B operating license, enhancing its operational stability and supply of Cobalt-60 [6] Company Strategy and Development Direction - The company is focused on maintaining a strong balance sheet, having paid down $75 million of debt and lowered interest expenses by approximately $13 million annually [5][12] - The outlook for 2025 includes maintaining revenue growth expectations of 4.5%-6% and raising adjusted EBITDA growth outlook to 6.75%-7.75% [13][14] - The company aims to achieve a net leverage ratio target of two to three times, with improvements noted in the current ratio [12][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's guidance and outlook for the remainder of the year, despite some challenges in expert advisory services due to government funding issues [34][40] - The company anticipates continued growth in core lab testing and operational improvements, with expectations for Nelson Labs to return to growth in 2026 [62] Other Important Information - The company is actively managing litigation related to ethylene oxide emissions, with recent court rulings aligning with its defense strategy [17][18] - There are currently 83 personal injury claims in California, with trials expected to begin in January and April of 2027 [58] Q&A Session Summary Question: Volume recovery areas - Management noted consistent performance across Sterigenics and various categories, including bioprocessing and med tech, with expectations for continued volume recovery [24] Question: Litigation update - Management provided updates on ongoing cases in Illinois and Georgia, indicating progress and minimal personal injury claims in New Mexico [26] Question: Budget flush expectations - Management does not expect a budget flush from medtech customers and feels confident in their guidance for the remainder of the year [34] Question: Expert advisory services impact - Management acknowledged that expert advisory services are feeling headwinds from FDA funding issues, impacting the top line by about 10 points [39] Question: Nordion margin pressure - Management explained that margin pressure in Nordion is due to lower-margin product sales, but overall margins remain strong [50] Question: Sterigenics pricing trends - Management indicated that pricing for Sterigenics is stabilizing around 3.8%-4%, with potential for gradual improvement as capital investments are realized [55]

Core Insights - Westrock Coffee Company reported record quarterly segment performance, driven by the successful launch of a new single-serve cup plant and increased production at its extract and ready-to-drink facility in Conway, Arkansas [3][4] - The company reaffirmed its financial guidance for 2025 and 2026, indicating confidence in its operational strategy and market position [4] Financial Performance - Net sales for the second quarter reached $280.9 million, a 34.8% increase compared to the prior year [8] - Gross profit remained flat at $41.4 million, while the net loss widened to $21.6 million from $17.8 million in the previous year [8] - Consolidated Adjusted EBITDA was $15.3 million, which included $7.6 million in scale-up costs related to the Conway facility, compared to $12.4 million in the prior year [8][26] Segment Results - Beverage Solutions segment net sales increased by 27.9% to $208.8 million, with Segment Adjusted EBITDA rising by 48.5% to $19.7 million [8][21] - Sustainable Sourcing & Traceability segment net sales surged by 59.6% to $72.0 million, with Segment Adjusted EBITDA improving to $3.3 million from $0.4 million in the second quarter of 2024 [8][21] Cash Flow and Balance Sheet - Cash and cash equivalents increased to $43.96 million as of June 30, 2025, up from $26.15 million at the end of 2024 [12][19] - Total assets rose to $1.16 billion, compared to $1.10 billion at the end of 2024, reflecting growth in inventory and accounts receivable [12][19] Outlook - The company is focused on becoming a premier integrated supplier to leading coffee, tea, and energy beverage brands globally, with ongoing investments in production capabilities [3][4] - Westrock Coffee's secured net leverage ratio was reported at 4.75x, indicating the company's financial leverage in relation to its EBITDA [22][23]

Financial Performance - Elanco Animal Health reported first-quarter 2025 adjusted earnings per share of 37 cents, a 9% increase year over year, surpassing management guidance of 29 to 34 cents and consensus of 31 cents [1] - The company achieved sales of $1.19 billion, exceeding the consensus of $1.17 billion and management guidance of $1.16 billion to $1.18 billion, although sales decreased 1% on a reported basis but increased 4% on organic constant currency growth [1] Segment Performance - Pet Health revenue was $635 million, reflecting a 1% decrease on a reported basis but a 1% increase when excluding foreign exchange rates, with a 2% increase from price compared to Q1 2024 [2] - Farm Animal revenue was $546 million, a 2% decrease on a reported basis, but a 7% increase when excluding unfavorable impacts from aqua divestiture and foreign exchange rates, driven by a 3% increase from price [3] - First-quarter volumes for Farm Animal were up 4%, primarily due to strength in U.S. cattle, led by the product Experior [3] EBITDA and Leverage - Adjusted EBITDA was $276 million, a decrease of 6%, with an adjusted EBITDA margin of 23.1% compared to 24.4% a year ago [3] - As of March 31, Elanco's net leverage ratio was 4.4x adjusted EBITDA, an increase of 0.1x compared to December 31, 2024, with expectations of gross debt paydown of $450 million to $500 million in 2025 [4] Guidance and Future Outlook - The company raised its 2025 full-year revenue guidance from $4.45 billion to $4.51 billion, now expecting between $4.51 billion and $4.58 billion, compared to the consensus of $4.484 billion [7] - Elanco reaffirmed its 2025 adjusted EPS guidance of 80 to 86 cents, against the consensus of 83 cents, and expects second-quarter 2025 adjusted earnings of 17 to 21 cents, compared to the consensus of 25 cents [8] Market Context - The year-over-year volume decline in Q1 was primarily due to a challenging U.S. retail environment and decreased vaccine sales, offset by increased sales of new products and strong demand for parasiticide products in Europe [9] - The Advantage Family of products and Seresto contributed revenues of $123 million and $153 million, respectively [9]

Financial Data and Key Metrics Changes - The company's EBITDA from direct operations for Q1 2025 was $126 million, up from $95 million in Q1 2024, reflecting an EBITDA margin increase to 41% from 38% year-over-year [7] - Net income for Q1 2025 was $140 million, compared to $61 million in the same period last year [7] - The cash position at the end of the quarter was $648 million, with total debt of $862 million, resulting in a net leverage ratio of 0.46 times [8] Business Line Data and Key Metrics Changes - Silver production increased by 20% year-over-year to 3.7 million ounces, with 2.2 million ounces coming from Jumpak [9] - Copper production decreased by 21% year-over-year, primarily due to the processing of remaining inventories from the El Brocado pen pit [9] - Gold production fell to 27,980 ounces from 36,593 ounces in Q1 2024, mainly due to decreased output at Tambomayo and Orcopampa [9] Market Data and Key Metrics Changes - The all-in sustaining cost for Q1 2025 decreased by 83% compared to the same period last year, driven by lower commercial deductions and higher by-product rates [11] - Cash costs applicable to sales for copper and silver increased year-over-year, while gold cash costs rose primarily due to lower volumes and grades at Tambomayo and Orcopampa [12] Company Strategy and Development Direction - The company is focused on reserve growth, EBITDA maximization, and cost efficiency at flagship mines, with a strong pipeline of projects [16] - The San Gabriel project is on track, with 79% overall completion and expected to produce its first gold bar in Q4 2025, pending necessary permits [14][16] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of the San Gabriel project and its expected profitability, maintaining an internal rate of return (IRR) of around 12% to 13% [20][21] - The company anticipates an increase in capital expenditures for 2025, now expected to be between $400 million and $420 million, due to additional costs associated with San Gabriel [34] Other Important Information - The company received $49 million in dividends related to its stake in Cerro Verde [8] - Exploration expenses for 2025 are projected to be around $40 million to $45 million for operating units and $20 million for non-operating areas [28] Q&A Session Summary Question: Clarification on San Gabriel CapEx and expected returns - Management confirmed that the CapEx increase in 2025 is due to geotechnical and hydraulic issues, with total CapEx for the project now estimated between $720 million and $750 million, maintaining profitability at $1,600 gold prices [20][21] Question: Exploration budget and administrative expenses - The exploration budget for operating units is expected to be $40 million to $45 million for the year, with administrative expenses projected at $60 million to $65 million due to higher worker participation from increased profits [28][29] Question: Update on underground operations and training - The company is on track with underground training and development, with 60,000 tons of ore material on the surface and plans to hire new crews by July [45][46] Question: Status of permits and construction at Comalache - Construction permits were granted in March, and construction began in April, with expectations to start piling fresh ore by August [51]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 increased by 4.2% year-over-year to $774 million, with full-year revenue exceeding $3.1 billion, marking a 7.7% increase over 2023 [8][21] - Same facility patient days grew by 3.2% in Q4, remaining stable between 3% and 4% throughout the quarter [8][21] - Adjusted EBITDA for Q4 2024 was $153.1 million, with an adjusted EBITDA margin of 19.8%, down from 22.8% in the same quarter last year [22][23] - Adjusted income attributable to Acadia stockholders per diluted share was $0.64 for Q4 2024, compared to $0.85 for the prior year period [25] Business Line Data and Key Metrics Changes - Same facility revenue grew by 4.7% compared to Q4 2023, driven by patient day growth and a 1.4% increase in revenue per patient day [21] - Startup losses related to new facilities were $11.2 million in Q4 2024, a $6 million year-over-year increase [23] Market Data and Key Metrics Changes - The company reported a more stable labor environment in 2024, which supported recruitment and retention initiatives [9] - The company anticipates adding between 800 and 1,000 total beds in 2025, continuing to address the mental health and addiction crisis in the U.S. [18][19] Company Strategy and Development Direction - The company is focused on transforming patient care and has invested heavily in technology to enhance safety and care delivery [11][12] - Acadia's growth strategy includes completing construction on approximately 1,300 beds in 2024, with 776 of these beds becoming operational [15][17] - The company aims to maintain a balanced approach to growth and free cash flow generation, expecting to return to free cash flow positive by the end of 2026 [42][43] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and goals, emphasizing the importance of expanding access to specialized care [19] - The outlook for 2025 includes revenue guidance of $3.3 billion to $3.4 billion and adjusted EBITDA guidance of $675 million to $725 million [27][28] - Management acknowledged challenges from underperforming facilities but maintained a cautious approach to guidance [29][30] Other Important Information - The company has authorized a new $300 million share repurchase program, which will be executed based on market conditions [44] - The company expects capital spending in the range of $630 million to $690 million for 2025, with a significant portion allocated to expansion spending [28] Q&A Session Summary Question: Can you provide insights on financing plans and cash flow expectations? - Management confirmed refinancing existing bank facilities and upsizing to about a billion dollars, with expectations of returning to cash flow positive by the end of 2026 [47][48] Question: How do you view the growth outlook and margin assumptions post-2025? - Management expects revenue growth of 7% to 9% and EBITDA growth of 8% to 10% in the years following 2025, with a focus on balancing capital expenditures and free cash flow [62][66] Question: What is the current status of referral activity and its impact on growth? - Management reported that referral issues are less of a challenge now, with ongoing efforts to improve relationships with key referral sources [99][102] Question: What actions are being taken to improve underperforming facilities? - Management is conducting comprehensive reviews of underperforming facilities, focusing on business development, leadership, and technology adoption [118][122]

Financial Performance - Organic net sales decreased by 2% compared to the previous year, reaching $3,024 million[11, 48] - Adjusted gross margin improved by 52 bps to 28.7%[11, 45] - Adjusted operating margin decreased by 49 bps to 16.4%[11, 45] - Adjusted EPS decreased by 9.2% to $0.69[11, 45] Cost Savings and Cash Flow - Year-to-date cost savings amounted to 4% of Total Cost of Goods Sold[10, 13] - Year-to-date free cash flow conversion was 124%[10, 59] - Net leverage ratio decreased from 3.65x to 3.44x[39, 57] Segment Performance - Grocery & Snacks net sales increased by 3.4%[48] - Refrigerated & Frozen net sales decreased by 8.1%[48] - International net sales increased by 1%[37, 48] - Foodservice net sales decreased by 1%[37, 48] Investments and Innovation - Increased advertising & promotion (A&P) investment by 6.5%, representing 2.8% of net sales[45] - Conagra's portfolio holding or gaining unit share increased by 12 percentage points to 51.9%[23] Updated Guidance - Organic net sales growth is projected to be between -1% and -2% for fiscal year 2024[41, 60] - Adjusted operating margin is expected to be approximately 15.8% for fiscal year 2024[41, 60] - Adjusted EPS is projected to be between $2.60 and $2.65 for fiscal year 2024[41, 60]